Breast Ultrasound Market Size & Share 2026-2035

Breast Ultrasound Market Size

The global breast ultrasound market is valued at USD 3.5 billion in 2025 and is projected to increase from USD 3.7 billion in 2026 to USD 7.6 billion by 2035, at a CAGR of 8.3% over 2026-2035.

Breast ultrasound demand is increasingly linked to the gap between mammographic screening and lesion visibility in dense breast tissue. Breast cancer caused an estimated 2.3 million new cases and approximately 670,000 deaths worldwide in 2022, establishing a large and persistent diagnostic imaging need across mature screening systems and countries expanding early-detection capacity ^{[1]International Agency for Research on Cancer, Global cancer burden estimates 2022, iarc.who.int}. In the U.S., the FDA began enforcing standardized breast-density notification requirements on September 10, 2024, requiring mammography facilities to inform patients about breast density and the potential value of discussing supplemental imaging with a healthcare provider ^{[2]U.S. Food and Drug Administration, Final Rule to Amend the Mammography Quality Standards Act, fda.gov}. Dense breast tissue both reduces mammographic sensitivity and is common enough to make supplemental-imaging pathways operationally significant for imaging providers .

Automated breast ultrasound systems have broadened the modality's role from focused diagnostic evaluation to standardized supplemental screening. A meta-analysis of 3D automated breast ultrasound used alongside mammography found higher cancer detection than mammography alone in women with dense breasts . This evidence supports investment in volumetric acquisition, dedicated reading workstations, and workflow tools that allow image acquisition and interpretation to occur at different locations.

Automated systems are positioned to capture a substantial share of incremental spending because they standardize acquisition and create a reviewable 3D dataset. That advantage matters most where facilities can spread equipment, service, software, and specialist-reading costs across high screening volumes. Conventional ultrasound remains indispensable for targeted examination and intervention, leaving the market's growth pattern dependent on two complementary use cases rather than a simple replacement cycle.

Key Drivers

Growing prevalence of breast cancer worldwide

Breast cancer incidence sustains equipment demand because ultrasound is used across several points in the care pathway: clarification of mammographic findings, evaluation of palpable abnormalities, image-guided biopsy, treatment monitoring, and supplemental screening. IARC reported that incidence increased by 1-5% annually in 27 of 50 countries with sufficient recent historical data, highlighting that demand is rising in both established screening markets and countries still building diagnostic infrastructure ^{[3]International Agency for Research on Cancer, Breast cancer cases and deaths projected to rise globally, iarc.who.int}.

The disease burden is concentrated in countries that are central to regional demand. China recorded 357,161 new female breast cancer cases in 2022, followed by the U.S. at 274,375 and India at 192,020 . The American Cancer Society projects 316,950 new invasive breast cancer cases among U.S. women in 2025 , while registry-based research estimated 238,085 new female breast cancer cases in India in 2024 . These volumes support both high-throughput institutional purchases and lower-cost conventional ultrasound deployment in markets where mammography access remains uneven.

Rising technological advancements in breast ultrasound systems

Three-dimensional automated acquisition, elastography, image-processing tools, and AI-enabled lesion assessment are changing the economics of breast ultrasound. Automated systems capture whole-breast volumetric datasets that can be reviewed in multiple planes, reducing dependence on real-time physician scanning and supporting more consistent screening workflows . GE HealthCare's Invenia ABUS 2.0 has FDA premarket approval for supplemental screening in asymptomatic women with dense breast tissue , while the company positions the platform around standardized acquisition and reading workflow integration .

AI capability is extending across both conventional and automated platforms. Peer-reviewed literature indicates that AI can assist lesion detection, classification, image-quality evaluation, and reporting consistency in breast ultrasound, although clinical deployment remains dependent on validation, reader oversight, and local workflow design ^{[4]American Journal of Roentgenology, Artificial Intelligence for Breast Ultrasound, ajronline.org}. This makes software functionality commercially relevant beyond image quality alone: it can influence reading capacity, training burden, and the ability to support distributed imaging networks.

Tele-ultrasound and teleradiology are especially relevant where qualified breast-imaging readers are scarce. Philips' Collaboration Live platform supports real-time remote communication during ultrasound examinations , and a study of 5G-based telerobotic breast ultrasound found that remote examinations could provide image quality comparable with conventional in-center scanning in the evaluated settings . These models do not remove the need for trained acquisition staff and governance, but they can make specialist interpretation available beyond tertiary hospitals.

Rising awareness and favorable government initiatives regarding breast cancer

Screening policy is expanding the pool of women entering breast-imaging pathways. The U.S. Preventive Services Task Force recommends biennial mammography screening for women aged 40-74 years . The recommendation increases the number of women exposed to routine mammography and, consequently, the number receiving density-related findings that may lead to individualized discussions about supplemental imaging.

Government-led awareness and screening initiatives also matter in emerging markets because they influence whether diagnostic demand is concentrated in late-stage symptomatic care or shifts toward earlier detection. India's registry evidence shows a substantial breast cancer burden across its population , while China's scale of disease creates a strong rationale for screening models that can pair local image acquisition with centralized interpretation . Ultrasound vendors that can support training, quality assurance, and remote reading may be better aligned with these programs than suppliers focused only on capital-equipment placement.

Increased reimbursement for breast ultrasound in the U.S

Reimbursement determines whether a clinically supported supplemental-imaging pathway can be sustained at facility level. CMS Local Coverage Determination L33950 defines medical-necessity criteria for breast imaging, including diagnostic ultrasonography . For ABUS providers, coding and payer-policy guidance helps translate dense-breast referrals into billable services, although payment remains dependent on patient circumstance, payer policy, and applicable state requirements .

The commercial effect is strongest for hospitals and specialized imaging centers that can combine reimbursement infrastructure with sufficient patient volume. Clearer documentation of breast density, a defined diagnostic pathway, and available coding guidance can reduce administrative uncertainty. It does not eliminate capital constraints, particularly for independent providers that must absorb equipment, service, software, and staffing costs before utilization reaches scale.

Key Restraints

High cost of automated breast ultrasound system device

Premium ABUS platforms require more than an acquisition unit. Procurement may include dedicated transducers, reading workstations, integration with enterprise imaging systems, software licenses, service agreements, and staff education. The total-cost burden is therefore materially different from that of a general-purpose handheld ultrasound unit. Automated systems provide standardized volumetric screening capability, but their financial case depends on examination volume, reimbursement certainty, and the availability of readers trained to review 3D datasets .

This barrier is pronounced in community facilities and price-sensitive public-health systems. Leasing, per-procedure arrangements, and software subscriptions can reduce the initial capital hurdle, but they shift the decision toward recurring operating expenditure. Suppliers that can demonstrate pathway-level efficiency, rather than relying only on technical specifications, are likely to have an advantage in these accounts.

Lack of skilled or trained personnel in developing and underdeveloped regions

Automated acquisition reduces some operator variability but does not eliminate the need for appropriate positioning, compression, quality checks, artifact recognition, and escalation protocols. Interpretation also requires comfort with multiplanar review and breast-specific reporting conventions. The UK BRAID trial identified training and systematic quality assurance as essential conditions for introducing ABUS as an additional dense-breast screening tool .

The workforce constraint is geographically uneven. Specialist readers tend to be concentrated in urban referral centers, while outreach programs often operate in locations with the greatest access gaps. Teleradiology can partially address this mismatch, but it requires reliable connectivity, secure image transfer, accountable reporting pathways, and local personnel able to acquire diagnostically adequate images . Consequently, personnel shortages can slow adoption even where cancer burden and clinical demand are substantial.

This divergence favors different commercial models by region. High-volume institutions can justify automated platforms through standardized workflow and centralized reading, whereas community programs may prioritize portable conventional systems, training support, and remote specialist access. Teleradiology can extend expertise, but it is most effective when vendors and providers treat connectivity, quality control, and reader capacity as integral parts of the imaging offering.

Breast Ultrasound Market Segment Analysis

By Type

Conventional ultrasound accounted for approximately 34.9% of market revenue in 2025. Its position rests on real-time scanning, targeted examination of palpable or mammographically detected findings, and direct support for image-guided biopsy or aspiration. These are interactive clinical tasks that standardized automated screening protocols do not fully replace.

The segment also benefits from lower entry costs and portability. In community facilities, mobile screening settings, and markets with constrained capital budgets, conventional systems remain the more practical route to breast-imaging access. AI-assisted lesion characterization and elastography are improving the capability of these systems, but the core commercial proposition remains diagnostic flexibility rather than population-screening throughput.

Automated ultrasound held approximately 65.1% of market revenue in 2025, equivalent to approximately USD 2.3 billion. Its leading revenue position reflects higher system value, growing use in dense-breast supplemental screening, and compatibility with centralized reading models. Evidence supporting additional cancer detection when 3D ABUS is combined with mammography has made the modality more relevant to institutions designing standardized supplemental-imaging pathways ^{[5]MDPI, Automated 3D Ultrasound as an Adjunct to Screening Mammography Programs in Dense Breast, mdpi.com}.

The segment's economics favor organizations that can maintain utilization across multiple sites or patient cohorts. Standardized acquisition enables technologists to create datasets for later review by breast-imaging specialists, allowing reading expertise to be centralized. FDA-approved systems such as GE HealthCare's Invenia ABUS 2.0 and Delphinus Medical Technologies' SoftVue demonstrate that the automated category includes different technical approaches, from volumetric ultrasound to ultrasound tomography , .

By End Use

Hospitals represented 45.6% of market revenue in 2024. Their leading position reflects high patient volume, access to oncology and surgical services, established radiology infrastructure, and the ability to integrate imaging with biopsy, pathology, and treatment planning. Hospitals can also centralize ABUS reading across satellite facilities, improving the utilization of scarce breast-imaging specialists.

Diagnostic laboratories accounted for 30.2% of market revenue in 2024. Dedicated imaging centers often have the focused case mix needed to support ABUS utilization, especially in markets with defined reimbursement pathways. Their economics are sensitive to payer coverage and reader productivity, which makes workflow software and teleradiology integration important procurement considerations.

Other end users held 24.1% of market revenue in 2024. This category includes specialty clinics, research institutions, mobile screening providers, and government or community screening programs. The segment is heterogeneous: academic centers may evaluate novel automated systems, while outreach programs may prioritize portable conventional ultrasound or compact automated technologies. iSono Health's FDA-cleared wearable ATUSA system illustrates the interest in automated whole-breast imaging formats designed for settings with limited sonographer availability ^{[6]Business Wire, FDA clearance of iSono Health ATUSA automated wearable 3D breast ultrasound, businesswire.com}.

End-use economics amplify this distinction. Hospitals can spread ABUS costs across broad imaging networks and integrate results into oncology pathways, while diagnostic laboratories may prioritize the productivity of each reading workstation and reimbursement-supported examination. Smaller and outreach-oriented providers will continue to support demand for conventional and compact systems, making product portfolios that span both workflows strategically valuable.

Breast Ultrasound Market Regional Analysis

North America

North America represented approximately 34% of global market revenue in 2025, valued at approximately USD 1,190 million. The U.S. market was valued at USD 819.8 million in 2022, USD 945.3 million in 2023, USD 1,009.7 million in 2024, and USD 1,081.1 million in 2025. The region's scale reflects established screening infrastructure, high availability of advanced imaging technology, and a regulatory environment that makes breast density a more consistent part of patient communication.

The FDA's national dense-breast notification requirement and the USPSTF screening recommendation strengthen the operational relevance of supplemental-imaging capacity , . Canada contributes through provincial screening and diagnostic pathways, although procurement and reimbursement conditions vary by province. Across North America, ABUS adoption is most attractive to networks able to combine equipment placement with trained readers, enterprise imaging integration, and reliable payer processes.

Europe

Europe accounted for approximately 26% of global market revenue in 2025, valued at USD 910.6 million. Germany, the UK, France, Spain, Italy, and the Netherlands form the core regional markets. Country-level variation in reimbursement and screening practice means adoption is not uniform, even where vendors have broad device availability.

The BRAID trial in the UK illustrates the regional implementation challenge: ABUS may add screening capacity for women with dense breasts, but its use requires defined training, acquisition quality assurance, and reading protocols ^{[7]Clinical Radiology, Introduction of ABUS as an Additional Screening Tool for Dense Breasts in the UK, sciencedirect.com}. Fujifilm expanded its European DeepInsight offering in November 2024 through compatibility with CMUT probes for ARIETTA 750 and ARIETTA 850 DeepInsight systems . European demand is therefore likely to depend on local evidence generation and workflow integration rather than a single region-wide reimbursement trigger.

Asia Pacific

Asia Pacific held approximately 28% of market revenue in 2025 and is expected to grow at approximately 8.3% CAGR through the forecast period. China, India, Japan, South Korea, and Australia are the principal markets. China's very high absolute breast cancer incidence and India's growing documented burden provide a large clinical base for imaging demand , .

The region's opportunity is shaped by the distribution of specialist capacity. China has demonstrated community-screening models that combine local ultrasound acquisition with cloud-based or centralized interpretation, which could support wider reach where breast-imaging expertise is concentrated in major cities ^{[8]Radiology Business, Teleradiology-backed breast cancer screening program, radiologybusiness.com}. Mindray reported 8.8% growth in its medical imaging systems segment in 2023 and stated that high-end ultrasound product lines grew by more than 20%; the company launched the Resona A20 in China with Acoustic Intelligence Technology and Smart Breast AI . Japan, South Korea, and Australia offer more mature imaging ecosystems, while India's development potential is more closely tied to affordable access, training, and teleradiology infrastructure.

Latin America

Latin America represented approximately 6-7.6% of global market revenue in 2025. Brazil, Mexico, and Argentina are the principal markets. Brazil's 2022 breast cancer burden was substantial, reinforcing the clinical need for accessible diagnostic imaging . However, public procurement limitations, import costs, and uneven reimbursement reduce the pace at which advanced automated systems can replace conventional ultrasound.

Hospitals and private imaging networks in large urban centers are likely to be the first buyers of premium ABUS platforms, while conventional systems retain a broader role in public-sector and community settings. The region's adoption curve will therefore depend as much on financing and service models as on technical performance.

Middle East and Africa

The Middle East and Africa accounted for approximately 3.1-3.8% of global revenue in 2025. Saudi Arabia, the UAE, and South Africa provide the main current demand centers. GCC healthcare investments support demand for advanced imaging in major hospital systems, while South Africa and other African markets face wider affordability and workforce constraints.

CapeRay's Aceso platform represents an approach designed around integrated breast imaging: the company describes a system that combines full-field digital mammography and automated breast ultrasound in one examination workflow, while also developing the Aegle platform concept . Such integrated designs may be relevant where separate imaging appointments create logistical barriers, although adoption still depends on procurement resources, clinical evidence, and local regulatory progress.

Latin America and the Middle East and Africa remain commercially important despite smaller current revenue shares. Their markets reward flexible product architectures, financing options, and service models that accommodate uneven infrastructure. For suppliers, regional success will depend less on exporting a single premium-platform strategy than on matching acquisition technology, clinical training, and reading workflows to the local care-delivery model.

Breast Ultrasound Market Share & Competitive Landscape

Samsung Electronics Co. Ltd., GE HealthCare, Canon Medical Systems Corporation, Koninklijke Philips N.V., and Siemens Healthineers AG collectively hold approximately 70% of global market share. Their position reflects installed imaging bases, distribution reach, enterprise workflow capability, and the ability to combine ultrasound hardware with AI, visualization, and service offerings.

Samsung Electronics Co. Ltd operates through Samsung Medison in breast ultrasound. Its RS85 Prestige platform includes S-Detect for Breast, Live BreastAssist, and S-Shearwave Imaging capabilities intended to support lesion assessment and standardized imaging workflows .

GE HealthCare markets the Invenia ABUS portfolio for supplemental screening in women with dense breasts. In July 2024, the company announced an agreement to acquire the clinical AI business of Intelligent Ultrasound Group PLC for approximately USD 51 million, reinforcing its focus on AI-enabled ultrasound workflows ^{[9]GE HealthCare, Agreement to acquire clinical AI business from Intelligent Ultrasound Group, gehealthcare.com}.

Canon Medical Systems Corporation competes through the Aplio platform family. Its Aplio i-series Prism Edition incorporates Third Harmonic Imaging and other image-processing functions intended to enhance visualization and reduce artifacts .

Koninklijke Philips N.V offers breast-imaging capabilities through the EPIQ Elite Elevate and Affiniti Elevate systems. Its portfolio includes KOIOS AI integration, Anatomical Intelligence for Breast, ElastQ imaging, and tele-ultrasound functionality through Collaboration Live.

Siemens Healthineers AG provides automated breast volume scanning through the ACUSON S2000 ABVS and reading workflow support through syngo.Ultrasound Breast Analysis, which enables multiplanar review and comparison of breast ultrasound datasets , .

FujiFilm Holdings Corporation markets the ARIETTA DeepInsight family, including the ARIETTA 850 DI, 750 DI, and 650 DI. The portfolio applies DeepInsight image processing to improve signal presentation and tissue differentiation .

Recent Industry Developments

• July 2024: GE HealthCare announced an agreement to acquire the clinical AI business of Intelligent Ultrasound Group PLC for approximately USD 51 million. The transaction targets AI-enabled image-recognition capabilities relevant to women's health ultrasound and other clinical applications .
• September 2024: The FDA began enforcing the MQSA final rule on September 10, 2024. The rule requires FDA-certified mammography facilities to provide standardized breast-density notification to patients and healthcare providers .